A Phase Iiib, Randomized, Multicenter, Active-Controlled, Parallel-Gro
Research payments
$5,616,837
Through program year 2023, $5,616,837 in research payments was reported against A Phase Iiib, Randomized, Multicenter, Active-Controlled, Parallel-Gro, across 1,248 payments, paid by ViiV Healthcare Company.
- Paid by
- ViiV Healthcare Company
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $671,213 | 229 |
| 2022 | Research | $1,500,285 | 512 |
| 2021 | Research | $3,385,037 | 492 |
| 2020 | Research | $60,302 | 15 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Mitchell Whitehead Pensacola, FL Named on 53 payments
- Robert Grossberg Bronx, NY Named on 37 payments
- Archana Asundi Boston, MA Named on 33 payments
- Michael Frank Milwaukee, WI Named on 28 payments
- Joan Duggan Monroe, MI Named on 26 payments
- Allison Bearden Los Angeles, CA Named on 26 payments
- Olayemi Osiyemi West Palm Beach, FL Named on 24 payments
- Onyema Ogbuagu New Haven, CT Named on 24 payments
- Gordon Crofoot Houston, TX Named on 22 payments
- Mehri McKellar Los Angeles, CA Named on 22 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.